Live cell detection of chromosome 2 deletion and Sfpi1/PU1 loss in radiation-induced mouse acute myeloid leukaemia

Leukemia Research

Volumn 37, Issue 10, 2013, Pages 1374-1382

  Olme, C H ^a   Finnon, R ^a   Brown, N ^a   Kabacik, S ^a   Bouffler, S D ^a   Badie, C ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Chromosome deletion; Live cells; Mouse model; Myeloid leukaemia; Radiation; Sfpi1 PU.1

Indexed keywords

GREEN FLUORESCENT PROTEIN; TRANSCRIPTION FACTOR PU 1;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CHROMOSOME 2; CHROMOSOME DELETION; CONTROLLED STUDY; COPY NUMBER VARIATION; EXON; FEMALE; FLOW CYTOMETRY; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ENGINEERING; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; HETEROZYGOSITY; HOMOZYGOSITY; LEUKEMIA CELL; LEUKEMOGENESIS; LIVE LEUKEMIC CELL; MALE; MOUSE; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; RADIATION INDUCED NEOPLASM; SFPI1 GENE; X RAY;

CHROMOSOME DELETION; LIVE CELLS; MOUSE MODEL; MYELOID LEUKAEMIA; RADIATION; SFPI1/PU.1;

ANIMALS; BONE MARROW CELLS; CHROMOSOME DELETION; DISEASE MODELS, ANIMAL; EXONS; FEMALE; FLOW CYTOMETRY; GENE DELETION; GENE EXPRESSION; GENES, REPORTER; GENETIC PREDISPOSITION TO DISEASE; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, RADIATION-INDUCED; MICE; MUTATION; PROTO-ONCOGENE PROTEINS; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC;

EID: 84883554367     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.05.019     Document Type: Article

References (50)

1. Leone G., Pagano L., Ben-Yehuda D., Voso M.T. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007, 92:1389-1398.
2. Gilbert E.S. Ionizing radiation and cancer risks: what have we learned from epidemiology. Int J Radiat Biol 2009, 85:467-482.
3. Sill H., Olipitz W., Zebisch A., Schulz E., Wölfler A. Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. Brit J Pharmacol 2011, 162:792-805.
4. Ron E., Preston D.L., Mabuchi K., Thompson D.E., Soda M. Cancer incidence in atomic bomb survivors. Part IV: Comparison of cancer incidence and mortality. Radiat Res 1994, 137(2 Suppl.):S98-S112.
5. Pierce D.A., Shimizu Y., Preston D.L., Vaeth M., Mabuchi K. Studies of the mortality of atomic bomb survivors. Report 12. Part I. Cancer: 1950-1990. Radiat Res 1996, 146:1-27.
6. Major I.R., Mole RH Myeloid leukaemia in X-ray irradiated CBA mice. Nature 1978, 272:455.
7. Rithidech K., Bond V.P., Cronkite E.P., Thompson M.H., Bullis J.E. Hypermutability of mouse chromosome 2 during the development of X-ray-induced murine myeloid leukemia. Proc Natl Acad Sci USA 1995, 92:1152-1156.
8. Azumi J., Sachs L. Chromosome mapping of the genes that control differentiation and malignancy in myeloid leukemic cells. Cancer 1977, 74:253-257.
9. Hayata I., Seki M., Yoshida K., Hirashima K., Sado T., Yamigawa J., et al. Chromosomal aberrations observed in 52 mouse myeloid leukemias. Cancer Research 1983, 43:367-373.
10. Trakhtenbrot L., Krautgamer R., Resnitzky P., Haran-Ghera N. Deletion of chromosome 2 is an early event in the development of radiation-induced myeloid leukemia. Leukemia 1988, 2:545-550.
11. Hirouchi T., Takabatake T., Yoshida K., Nitta Y., Nakamura M., Tanaka S., et al. Upregulation of c-myc gene accompanied by PU.1 deficiency in radiation-induced acute myeloid leukemia in mice. Exp Hematol 2008, 36:871-885.
12. Bouffler S.D., Breckon G., Cox R. Chromosomal mechanisms in murine radiation acute myeloid leukaemogenesis. Carcinogenesis 1996, 17:655-659.
13. Bouffler S.D., Meijne E.I.M., Morris D.J., Papworth D. Chromosome 2 hypersensitivity and clonal development in murine radiation acute myeloid leukaemia. Int J Radiat Biol 1997, 72:181-189.
14. Peng Y., Brown N., Finnon R., Warner C.L., Liu X., Genik P.C., et al. Radiation leukemogenesis in mice: loss of PU.1 on chromosome 2 in CBA and C57BL/6 mice after irradiation with 1GeV/nucleon 56Fe ions, X rays or γ rays Part I. Experimental observations. Radiat Res 2009, 171:474-483.
15. Cook W.D., McCaw B.J., Herring C., John D.L., Foote S.J., Nutt S.L., et al. PU.1 is a suppressor of myeloid leukemia, inactivated in mice by gene deletion and mutation of its DNA binding domain. Blood 2004, 104:3437-3444.
16. Suraweera N., Meijne E., Moody J., Carvajal-Carmona L.G., Yoshida K., Pollard P., et al. Mutations of the PU.1 Ets domain are specifically associated with murine radiation-induced, but not human therapy-related, acute myeloid leukaemia. Oncogene 2005, 24:3678-3683.
17. Hromas B.R., Orazi A., Neiman R.S., Maki R., Van Beveran C., Moore J., et al. Hematopoietic lineage- and stage-restricted expression of the ETS oncogene family member PU.1. Blood 1993, 82:2998-3004.
18. Kastner P., Chan S. PU.1: a crucial and versatile player in hematopoiesis and leukemia. Int J Biochem Cell Biol 2008, 40:22-27.
19. DeKoter R.P., Singh H. Regulation of B lymphocyte and macrophage development by graded expression of PU.1. Science 2000, 288:1439-1441.
20. Dahl R., Walsh J.C., Lancki D., Laslo P., Iyer S.R., Singh H., et al. Regulation of macrophage and neutrophil cell fates by the PU. 1: C/EBPalpha ratio and granulocyte colony-stimulating factor. Nat Immunol 2003, 4:1029-1036.
21. Rosenbauer F., Wagner K., Kutok J.L., Iwasaki H., Le Beau M.M., Okuno Y., et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU. 1. Nat Genet 2004, 36:624-630.
22. Metcalf D., Dakic A., Mifsud S., Di Rago L., Wu L., Nutt S. Inactivation of PU.1 in adult mice leads to the development of myeloid leukemia. Proc Natl Acad Sci USA 2006, 103:1486-1491.
23. Finnon R., Brown N., Moody J., Badie C., Olme C.-H., Huiskamp R., et al. Flt3-ITD mutations in a mouse model of radiation-induced acute myeloid leukaemia. Leukemia 2012, 26:1445-1446.
24. Inomata M., Takahashi S., Harigae H., Kameoka J., Kaku M., Sasaki T. Inverse correlation between Flt3 and PU.1 expression in acute myeloblastic leukemias. Leuk Res 2006, 30:659-664.
25. Brown N.L., Finnon R., Bulman R., Finnon P., Moody J., Bouffler S.D., et al. Sfpi1/PU.1 mutations in mouse radiation-induced acute myeloid leukaemias affect mRNA and protein abundance and associate with disrupted transcription. Leuk Res 2011, 35:126-132.
26. Alexander B.J., Rasko J.E., Morahan G., Cook W.D. Gene deletion explains both in vivo and in vitro generated chromosome 2 aberrations associated with murine myeloid leukemia. Leukemia 1995, 9:2009-2015.
27. Silver A., Moody J., Dunford R., Clark D., Ganz S., Bulman R., et al. Molecular mapping of chromosome 2 deletions in murine radiation-induced AML localizes a putative tumor suppressor gene to a 1.0 cM region homologous to human chromosome segment 11p11-12. Genes Chromosomes Cancer 1999, 24:95.
28. Nutt S.L., Metcalf D., Amico A.D., Polli M., Wu L. Dynamic regulation of PU.1 expression in multipotent hematopoietic progenitors. J Exp Med 2005, 201:221-231.
29. Back J., Allman D., Chan S., Kastner P. Visualizing PU.1 activity during hematopoiesis. Exp Hematol 2005, 33:395-402.
30. Dakic A., Metcalf D., Di Rago L., Mifsud S., Wu L., Nutt S.L. PU.1 regulates the commitment of adult hematopoietic progenitors and restricts granulopoiesis. J Exp Med 2005, 201:1487-1502.
31. Kogan S.C., Ward J.M., Anver M.R., Berman J.J., Brayton C., Cardigg R.D., et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood 2002, 100:238-245.
32. Holmes K.L., Otten G., Yokoyama W.M. Flow cytometry analysis using the Becton Dickinson FACS calibur. Curr Protoc Immunol 2001, 5.4.1-22.
33. Clark D., Meijne E., Bouffler S., Huiskamp R., Skidmore C.J., Cox R., et al. Microsatellite analysis of recurrent chromosome 2 deletions in acute myeloid leukaemia induced by radiation in FI hybrid mice. Genes Chromosomes Cancer 1996, 16:238-246.
34. Kabacik S., Ortega-Molina A., Efeyan A., Finnon P., Bouffler S., Serrano M., et al. A minimally invasive assay for individual assessment of the ATM/CHEK2/p53 pathway activity. Cell Cycle 2011, 10:1152-1161.
35. Kabacik S., Mackay A., Tamber N., Manning G., Finnon P., Paillier F., et al. Gene expression following ionising radiation: identification of biomarkers for dose estimation and prediction of individual response. Int J Radiat Biol 2010, 87:115-129.
36. Weil M.M., Bedford J.S., Bielefeldt-Ohmann H., Ray F.A., Genik P.C., Ehrhart E.J., et al. Incidence of acute myeloid leukemia and hepatocellular carcinoma in mice irradiated with 1GeV/nucleon 56Fe ions. Radiat Res 2009, 172:213-219.
37. Major I.R. Induction of myeloid leukaemia by whole-body single exposure of CBA male mice to X-rays. Brit J Cancer 1979, 40:903-913.
38. Iwasaki H., Akashi K. Myeloid lineage commitment from the hematopoietic stem cell. Immunity 2007, 26:726-740.
39. Jackson-Grusby L. Modeling cancer in mice. Oncogene 2002, 21:5504-5514.
40. Yu Y., Bradley A. Engineering chromosomal rearrangements in mice. Nat Rev Genet 2001, 2:780-790.
41. Tuveson D.A., Jacks T. Technologically advanced cancer modeling in mice. Curr Opin Genet Dev 2002, 12:105-110.
42. Goodhead D.T., Fifth Warren K. Sinclair keynote address: issues in quantifying the effects of low-level radiation. Health Phys 2008, 97:394-406.
43. Heinlein C., Deppert W., Braithwaite A., Speidel D. A rapid and optimization-free procedure allows the in vivo detection of subtle cell cycle and ploidy alterations in tissues by flow cytometry. Cell Cycle 2010, 9:3584-3590.
44. Brind'Amour J., Lansdorp P. Analysis of repetitive DNA in chromosomes by flow cytometry. Nat Methods 2011, 8:6-10.
45. Takizawa M., Kim J.S., Tessarollo L., et al. Genetic reporter system for oncogenic Igh-Myc translocations in mice. Oncogene 2010, 29:4113-4120.
46. Hirouchi T., Akabane M., Tanaka S., Braga-Tanaka I., Todate A., Ichinohe K., et al. Cell surface marker phenotypes and gene expression profiles of murine radiation-induced acute myeloid leukemia stem cells are similar to those of common myeloid progenitors. Radiat Res 2011, 176:311-322.
47. Poon G.M.K., Macgregor R.B. Base coupling in sequence-specific site recognition by the ETS domain of murine PU.1. J Mol Biol 2003, 328:805-819.
48. Mueller B.U., Pabst T., Osato M., Asou M., Johansen L.M., Minden M.D., et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 2002, 100:998-1007.
49. Mueller B.U., Pabst T., Fos J., Petkovic V., Fey M.F., Asou M., et al. ATRA resolves the differentiation block in t (15;17) acute myeloid leukemia by restoring PU.1 expression. Blood 2006, 107:3330-3338.
50. Bonadies N., Neururer C., Steege A., Vallabhapurapu S., Pabst T., Mueller B.U. PU.1 is regulated by NF-kappaB through a novel binding site in a 17kb upstream enhancer element. Oncogene 2010, 29:1062-1072.